References
- WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020. [updated 2020; cited July 26, 2020]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.
- Worldometer. Coronavirus Cases. Worldometer. p. 1–22. [cited 2020 Oct 22]. Available from: https://www.worldometers.info/coronavirus/.
- Rahmandad H, Lim T, Sterman J. EstimatingCOVID-19 under-reporting across 86 nations: implications for prevention and control. SSRN Electronic Journal. 2020; doi: 10.2139/ssrn.35047. [cited 2020 Aug 23]. Available at: http://ssrn.com/abstract=3635047
- WHO. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. 19 March 2020 [updated 2020; cited 2020 Jul 27] Available from: https://www.who.int/publications/i/item/10665-331495.
- Chen MJ, Chang KJ, Hsu CC, et al. Precaution and prevention of Coronavirus Disease 2019 infection in the eye. J Chin Med Assoc. 2020;83(7):648–650. [ cited Aug 10, 2020]. Available from:/pmc/articles/PMC7202097/?report = abstract%0A. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202097/..
- Javid B, Weekes MP, Matheson NJ. Covid-19: should the public wear face masks? BMJ. 2020;369:m1442. [cited 2020 Jul 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/32273278/
- Greenhalgh T, Schmid MB, Czypionka T, et al. Face masks for the public during the covid-19 crisis. BMJ. 2020;369:m1435
- Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: Important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020;369:m2003.
- Foo CCI, Goon ATJ, Leow YH, et al. Adverse skin reactions to personal protective equipment against severe acute respiratory syndrome-a descriptive study in Singapore. Contact Dermatitis. 2006;55(5):291–294. [Cited 2020 Aug 10]
- Moshirfar M, West WB, Marx DP. Face mask-associated ocular irritation and dryness. Ophthalmol Ther. 2020;9(3):397–400. doi:10.1007/s40123-020-00282-6.
- Foulks GN. The Correlation between the tear film lipid layer and dry eye disease. Surv Ophthalmol. 2007;52(4):369–374.
- Moss SE, Klein R, Klein BEK. Prevalance of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264–1268. doi:10.1001/archopht.118.9.1264.
- Wolkoff P, Nøjgaard JK, Franck C, et al. The modern office environment desiccates the eyes? Indoor Air. 2006;16(4):258–265. [cited Jul 27, 2020]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16842606.
- Alves M, Novaes P, de Andrade Morraye M, et al. Is dry eye an environmental disease? Arq Bras Oftalmol. 2014;77(3):193–200. [Cited 2020 Jul 27]
- Wolkoff P, Skov P, Franck C, et al. Eye irritation and environmental factors in the office environment-hypotheses, causes and a physiological model. Scand J Work Environ Health. 2003;29(6):411–430. [Cited 2020 Jul 27].
- Nakamura S, Shibuya M, Nakashima H, et al. Involvement of oxidative stress on corneal epithelial alterations in a blink-suppressed dry eye. Invest Ophthalmol Vis Sci. 2007;48(4):1552–1558. [Cited 2020 Jul 27].
- Chen X, Gallar J, Pozo MA, et al. CO2 Stimulation of the cornea: a comparison between human sensation and nerve activity in polymodal nociceptive afferents of the cat. Eur J Neurosci. 1995;7(6):1154–1163. [Cited 2020 Aug 15].
- Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. Faseb J. 1996;10(7):709–720. [Cited 2020 Aug 7]
- Xia C, Meng Q, Liu LZ, et al. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 2007;67(22):10823–10830. [Cited 2020 Aug 11].
- Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med. 2007;42(2):153–164. [Cited 2020 Aug 7].
- Pappas A. Epidermal surface lipids. Dermatoendocrinol. 2009;1(2):72–76. [cited 2020 Aug 15]. Available from: http://www.tandfonline.com/doi/abs/10.4161/derm.1.2.7811.
- Powell JB, Kim JH, Roberge RJ. Powered air-purifying respirator use in healthcare: Effects on thermal sensations and comfort. J Occup Environ Hyg. 2017;14(12):947–954.
- McMonnies CW. Incomplete blinking: exposure keratopathy, lid wiper epitheliopathy, dry eye, refractive surgery, and dry contact lenses. Cont Lens Anterior Eye. 2007;30(1):37–51. [cited 2020 Jul 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17251052
- Awisi-Gyau D, Begley CG, Situ P, et al. Changes in corneal detection thresholds after repeated tear film instability. Invest. Ophthalmol. Vis. Sci. 2019;60(13):4234–4240. doi:10.1167/iovs.19-27802.
- Pflugfelder SC, Stern ME. Biological functions of tear film. Exp Eye Res. 2020;197:108115. [Cited 2020 Aug 15].
- Aiello F, Gallo Afflitto G, Mancino R, et al. Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. Eye (Lond). 2020;34(7):1206–1211. [cited 2020 Jul 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32424327.
- Chen L, Deng C, Chen X, et al. Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: a cross-sectional study. medRxiv 2020. [cited 2020 Aug 16]. doi: 10.1101/2020.03.12.20034678.
- Chen L, Liu M, Zhang Z, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br J Ophthalmol. 2020;104(6):748–751.
- Zhang X, Chen X, Chen L, et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf. 2020;18(3):360–362.
- Guan W, Ni Z, Hu Y, China Medical Treatment Expert Group for Covid-19, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. [cited 2020 Jul 28]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2002032.
- Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5):575–578.
- Napoli PE, Nioi M, d’Aloja E, et al. The ocular surface and the Coronavirus Disease 2019: Does a dual ‘ocular route’ exist? JCM. 2020;9(5):1269. doi:10.3390/jcm9051269.
- Cheema M, Aghazadeh H, Nazarali S, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can J Ophthalmol. 2020;55(4):e125–e129. [Cited Aug 15].
- Dinkin M, Gao V, Kahan J, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020;95(5):221–223.
- Navel V, Chiambaretta F, Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2. Am J Ophthalmol Case Rep. 2020;19:100735.
- Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020;395(10237):1610.
- Insausti-García A, Reche-Sainz JA, Ruiz-Arranz C, et al. M. Papillophlebitis in a COVID-19 patient: Inflammation and hypercoagulable state. Eur J Ophthalmol 2020doi: 10.1177/1120672120947591.
- Douglas KAA, Douglas VP, Moschos MM. Ocular manifestations of COVID-19 (SARS-CoV-2): A Critical review of current literature. In Vivo. 2020;34(3 Suppl):1619–1628.
- Ho D, Low R, Tong L, et al. COVID-19 and the Ocular Surface: A review of transmission and manifestations. Ocul Immunol Inflamm. 2020;28(5):726–734.
- Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020;28(3):391–395. Accessed Jul 25, 2020
- Xie H-T, Jiang S-Y, Xu K-K, et al. SARS-CoV-2 in the ocular surface of COVID-19 patients. Eye Vis. (Lond.) 2020;7:23.
- Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92(6):589–594.
- Liang L, Wu P. There may be virus in conjunctival secretion of patients with COVID-19. Acta Ophthalmol. 2020;98(3):223–223. [cited 2020 Jul 28]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/aos.14413.
- Sun CB, Wang YY, Liu GH, et al. Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know. Front Public Health. 2020;8:155.
- Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing viral shedding and infectivity of tears in Coronavirus Disease 2019 (COVID-19) Patients. Ophthalmology. 2020;127(7):977–979. [Cited 2020 Jul 25].
- Colavita F, Lapa D, Carletti F, et al. SARS-CoV-2 Isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral rna detection. Ann Intern Med. 2020;173(3):242–243.
- Al-Sharif E, Strianese D, AlMadhi NH, et al. Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye. Int Ophthalmol. 2020; Sep 3: 1–14. doi: 10.1007/s10792-020-01575-2. [cited 2020 Sep 23].
- Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-NCOV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971.
- Schnichels S, Rohrbach JM, Bayyoud T, et al. [Can SARS-CoV-2 infect the eye?-An overview of the receptor status in ocular tissue] . Ophthalmologe. 2020;117(7):618–621.
- Lange C, Wolf J, Auw‐Haedrich C, et al. Expression of the COVID‐19 receptor ACE2 in the human conjunctiva. J Med Virol. 2020;92(10):2081–2086. ahead of p:2020;10.1002/jmv.25981. doi:10.1002/jmv.25981. [cited 2020 Jul 28]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25981.
- Sungnak W, Huang N, Bécavin C, HCA Lung Biological Network, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687.
- Savaskan E, Löffler KU, Meier F, et al. Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res. 2004;36(6):312–320.
- Zhou L, Xu Z, Castiglione GM, et al. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. Ocul Surf. 2020;18(4):537–544.
- Hui KPY, Cheung MC, Perera RAPM, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. 2020;8(7):687–695. doi:10.1016/S2213-2600(20)30193-4
- Coroneo MT. The eye as the discrete but defensible portal of coronavirus infection. Ocul Surf. 2020; doi:10.1016/j.jtos.2020.05.011. [cited 2020 Aug 13].
- Georgiev GA, Eftimov P, Yokoi N. Structure-function relationship of tear film lipid layer: A contemporary perspective. Exp Eye Res. 2017;163:17–28.
- Butovich IA. Tear film lipids. Exp Eye Res. 2013;117:4–27.
- Latalska M, Mackiewicz J. The implication of ocular manifestation of COVID-19 for medical staff and patients – systematic review. Ann Agric Environ Med. 2020;27(2):165–170. doi:10.26444/aaem/122790. [Cited 2020 Aug 7].
- Flanagan JL, Willcox MDP. Role of lactoferrin in the tear film. Biochimie. 2009;91(1):35–43.
- Chentoufi AA, Dasgupta G, Nesburn AB, et al. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4 + T-cell responses induced following topical ocular or intranasal immunization. CVI. 2010;17(3):342–353. doi:10.1128/CVI.00347-09. [Cited 2020 Jul 25].
- Orr-Burks N, Gulley SL, Gallardo RA, et al. Immunoglobulin a as an early humoral responder after mucosal avian coronavirus vaccination. Avian Dis. 2014;58(2):279–286.
- Tong TR, Lam BH, Ng TK, et al. Conjunctiva-upper respiratory tract irrigation for early diagnosis of severe acute respiratory syndrome. J Clin Microbiol. 2003;41(11):5352.
- Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. Geraghty RJ, ed. PLoS One. 2011;6(8):e23710. [Cited 2020 Jul 28]. Available from: https://dx.plos.org/10.1371/journal.pone.0023710.
- Milner MS, Beckman KA, Luchs JI, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - New strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;28(supplement 1):3–43. doi:10.1097/01.icu.0000512373.81749.b7.
- Yokoi N, Georgiev GA. Tear-film-oriented diagnosis for dry eye. Jpn J Ophthalmol. 2019;63(2):127–136.
- Essa L, Laughton D, Wolffsohn JS. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms? Contact Lens Anterior Eye. 2018;41(1):60–68. doi:10.1016/j.clae.2017.07.007.
- Çömez AT, Tufan HA, Kocabiyik Ö, et al. Effects of lubricating agents with different osmolalities on tear osmolarity and other tear function tests in patients with dry eye. Curr Eye Res. 2013;38(11):1095–1103. doi:10.3109/02713683.2013.806670. [Cited 2020 Aug 2].
- Lievens C, Berdy G, Douglass D, et al. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: a multicenter, double-masked, randomized 30-day study. Contact Lens Anterior Eye. 2019;42(4):443–449. doi:10.1016/j.clae.2018.12.003.
- Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefe's Arch Clin Exp Ophthalmol. 2005;243(6):531–538. doi:10.1007/s00417-004-1040-6.
- Groß D, Childs M, Piaton JM. Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis. OPTH. 2018;12:1081–1088. doi:10.2147/OPTH.S161578.
- McCann LC, Tomlinson A, Pearce EI, et al. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea. 2012;31(1):1–5. [Cited 2020 Jul 23].
- Diaz-Llopis M, Pinazo-Duran MD, Diaz-Guiñon L, et al. A randomized multicenter study comparing seawater washes and carmellose artificial tears eyedrops in the treatment of dry eye syndrome. OPTH. 2019;13:483–490. doi:10.2147/OPTH.S185409. [Cited 2020 Aug 2].
- Lee JH, Ahn HS, Kim EK, et al. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea. 2011;30(2):175–179.
- Guthrie SE, Jones L, Blackie CA, et al. A comparative study between an oil-in-water emulsion and nonlipid eye drops used for rewetting contact lenses. Eye Contact Lens. 2015;41(6):373–377.
- Bland HC, Moilanen JA, Ekholm FS, et al. Investigating the role of specific tear film lipids connected to dry eye syndrome: a study on O-Acyl-ω-hydroxy fatty acids and diesters. Langmuir. 2019;35(9):3545–3552. [Cited 2020 Aug 21].
- Scaffidi RC, Korb DR. Comparison of the efficacy of two lipid emulsion eyedrops in increasing tear film lipid layer thickness. Eye Contact Lens. 2007;33(1):38–44. [Cited 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17224677.
- Khanal S, Tomlinson A, Pearce EI, et al. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye. Cornea. 2007;26(2):175–181.
- Garrigue J-S, Amrane M, Faure M-O, et al. Relevance of lipid-based products in the management of dry eye disease. J Ocul Pharmacol Ther. 2017;33(9):647–661. [Cited 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28956698.
- Tsubota K, Monden Y, Yagi Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol. 1999;83(7):767–770. [Cited 2020 Aug 16].
- Maïssa C, Guillon M, Simmons P, et al. Effect of castor oil emulsion eyedrops on tear film composition and stability. Cont Lens Anterior Eye. 2010;33(2):76–82. [Cited 2020 Aug 18].
- Daull P, Amrane M, Ismail D, et al. Cationic emulsion-based artificial tears as a mimic of functional healthy tear film for restoration of ocular surface homeostasis in dry eye disease. J Ocul Pharmacol Ther. 2020;36(6):355–365. [Cited 2020 Aug 18].
- Fogagnolo P, Quisisana C, Caretti A, et al. Efficacy and safety of VisuEvo® and Cationorm® for the treatment of evaporative and non-evaporative dry eye disease: a multicenter, double-blind, cross-over, randomized clinical trial. Clin Ophthalmol. 2020;14:1651–1663. [Cited 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32606580.
- Daull P, Guenin S, de Almeida VH, et al. Anti-inflammatory activity of CKC-containing cationic emulsion eye drop vehicles - PubMed. Mol Vis. 2018;24:459–470. [cited 2020 August 18]. Available from: https://doi.org/https://pubmed.ncbi.nlm.nih.gov/30078983/.
- Craig JP, Purslow C, Murphy PJ, et al. Effect of a liposomal spray on the pre-ocular tear film. Contact Lens Anterior Eye. 2010;33(2):83–87. doi:10.1016/j.clae.2009.12.007. [Cited 2020 Aug 18].
- McKay TB, Karamichos D. Quercetin and the ocular surface: What we know and where we are going. Exp Biol Med (Maywood). 2017;242(6):565–572. [Cited 2020 Aug 19].
- Cejka C, Kubinova S, Čejková J. Trehalose in ophthalmology. Histol Histopathol. 2019;34(6):611–618. [Cited 2020 Aug 19].
- Cejka C, Kossl J, Hermankova B, et al. The healing of oxidative injuries with trehalose in UVB-irradiated rabbit corneas. Oxid Med Cell Longev. 2019;2019:1857086. [cited 2020 Aug 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31641422.
- Shetty R, Lalgudi VG, Khamar P, et al. Potential ocular and systemic COVID-19 prophylaxis approaches for healthcare professionals. Indian J Ophthalmol. 2020;68(7):1349–1356. [Cited 2020 Aug 18].
- Chen X, Li M, Li L, et al. Trehalose, sucrose and raffinose are novel activators of autophagy in human keratinocytes through an mTOR-independent pathway. Sci Rep. 2016;6(1):1–17. [cited 2020 Aug 31]. Available from: www.nature.com/scientificreports.
- MacKeen DL, Roth HW, Doane MG, et al. Supracutaneous treatment of dry eye patients with calcium carbonate. Adv Exp Med Biol. 1998;438:985–990.
- Zhang W, Wang Y, Lee BTK, et al. A novel nanoscale-dispersed eye ointment for the treatment of dry eye disease. Nanotechnology. 2014;25(12):125101 [cited 2020 Jul 29]. Available from: https://europepmc.org/article/med/24571862.
- Morrison PW, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv. 2014;5(12):1297–1315. [cited 2020 Aug 24]. Available from: http://www.future-science.com/doi/10.4155/tde.14.75.
- Mishra GP, Bagui M, Tamboli V, et al. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv. 2011;2011:863734– 863714. doi:10.1155/2011/863734. [cited 2020 Aug 22]. Available from:/pmc/articles/PMC3066533/?report = abstract.
- de Paiva CS, Pflugfelder SC, Ng SM, et al. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019;9(9):CD010051 [cited 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31517988.
- Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19(9):1027–1039.
- Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107(5):967–974.
- Stonecipher K, Perry HD, Gross RH, et al. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. 2005;21(7):1057–1063. doi:10.1185/030079905X50615. [cited 2020 Aug 21]. Available from: https://www.tandfonline.com/doi/abs/10.1185/030079905X50615.
- Pleyer U, Elkins B, Rückert D, et al. Ocular absorption of cyclosporine a from liposomes incorporated into collagen shields. Curr Eye Res. 1994;13(3):177–181. [cited 2020 Aug 21]. Available from: https://www.tandfonline.com/doi/abs/10.1185/030079905X50615.
- Agarwal R, Iezhitsa I, Agarwal P, et al. Liposomes in topical ophthalmic drug delivery: an update. Drug Deliv. 2016;23(4):1075–1091. [cited 2020 Aug 17]. Available from: https://www.tandfonline.com/doi/full/10.3109/10717544.2014.943336
- de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92(Pt 11):2542–2548. [cited 2020 Aug 23] Available from:/pmc/articles/PMC3352363/?report = abstract..
- Bhavsar AS, Bhavsar SG, Jain SM. Evaluation of the effects of chloroquine phosphate eye drops in patients with dry eye syndrome. Int J Biomed Adv Res. 2011;2(6):198–214. [cited 2020 Aug 31]. Available from: www.ijbar.ssjournals.com.
- Titiyal JS, Kaur M, Falera R, et al. Efficacy and safety of topical chloroquine in mild to moderate dry eye disease. Curr Eye Res. 2019;44(12):1306–1312. doi:10.1080/02713683.2019.1641824. [cited 2020 Aug 21]. Available from: https://www.tandfonline.com/doi/abs/10.1080/02713683.2019.1641824
- Ridder W, III, Karsolia A. New drugs for the treatment of dry eye disease. Clin Optom. 2015;7:102. [cited 2020 Aug 31]. Available from: https://www.dovepress.com/new-drugs-for-the-treatment-of-dry-eye-disease-peer-reviewed-article-OPTO
- Picot S, Marty A, Bienvenu AL, et al. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health. 2020;9:100131
- Hashem AM, Alghamdi BS, Algaissi AA, et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Med Infect Dis. 2020;35:101735
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. [cited 2020 Aug 23]. Available from: https://doi.org/10.1038/s41422-020-0282-0.
- Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. Available from:/pmc/articles/PMC1232869/?report = abstract%0A. [cited 2020 Aug 17]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/.
- Liu K, Tang M, Liu Q, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1–4. Available from: www.nature.com/celldisc.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949
- Wu R, Wang L, Kuo HCD, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020;6(3):56–70. doi:10.1007/s40495-020-00216-7. [cited 2020 Aug 23]. Available from: https://doi.org/10.1007/s40495-020-00216-7.
- Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non- human primates May. Journal Preprint Research Square. 2020. doi:10.21203/rs.3.rs-27223/v1 [cited 2020 Aug 23]. Available from: https://www.researchsquare.com/article/rs-27223/v1
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383(6):517–525. [cited 2020 Aug 22]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2016638.
- Waikar S, Oli A. COVID-19: Ophthalmic prophylactic and therapeutic measures. Indian J Ophthalmol. 2020;68(6):1223–1224. [cited 2020 Aug 17]. Available from: http://www.ijo.in/text.asp?2020/68/6/1223/284850.
- Haque RM, Torkildsen GL, Brubaker K, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29(8):871–877. [cited 2020 Aug 22]. Available from: http://journals.lww.com/00003226-201008000-00007.
- Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25(9):858–870.
- Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY)). 2020;12(8):6511–6517. [cited 2020 Aug 23]. Available from:/pmc/articles/PMC7202514/?report = abstract.
- Touret F, Gilles M, Barral K, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10(1):13093. doi:10.1038/s41598-020-70143-6. [Cited 2020 Aug 23]. Available from: https://doi.org/10.1038/s41598-020-70143-6.
- Damle B, Vourvahis M, Wang E, et al. Clinical Pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther. August 2020; 108(2):201–211. doi:10.1002/cpt.1857.
- Romanowski EG, Yates KA, Shanks RMQ, et al. Benzalkonium chloride demonstrates concentration-dependent antiviral activity against adenovirus in vitro. J Ocul Pharmacol Ther. 2019;35(5):311–314. doi:10.1089/jop.2018.01451.
- Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. [Cited 2020 Aug 21].
- Anderson D, Sivalingam V, Kang AEZ, et al. Povidone-iodine demonstrates rapid In vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease . Infect Dis Ther. 2020;9(3):669–675. [cited 2020 Aug 23]. Available from: https://doi.org/10.21203/rs.3.rs-34544/v1.
- Dev Kumar G, Mishra A, Dunn L, et al. Biocides and novel antimicrobial agents for the mitigation of coronaviruses. Front Microbiol. 2020;11:1351 [cited 2020 Aug 22]. Available from: www.frontiersin.org
- Kirk-Bayley J, Challacombe S, Sunkaraneni V, et al. The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may protect healthcare workers and reduce cross infection. SSRN Electronic J. 2020; doi: 10.2139/ssrn.3563092 [cited Sep 23].
- Mendoza L. Prevention of COVID-19 Infection with Povidone-Iodine. SSRN Electron J. 2020; doi: 10.2139/ssrn.3589404. [cited 2020 Sep 23]. Available from: https://ssrn.com/abstract=3589404
- Ramalingam S, Cai B, Wong J, et al. Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid levels. Sci Rep. 2018;8(1):1–11. doi:10.1038/s41598-018-31936-y
- Machado RRG, Glaser T, Araujo DB, et al. Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay. bioRxiv. 2020; doi:10.1101/2020.08.04.235549. [cited 2020 Sep 23].
- Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: Report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050–2064.
- Bonzano C, Borroni D, Lancia A, et al. Doxycycline: from ocular rosacea to COVID-19 anosmia. New Insight into the coronavirus outbreak. Front Med (Lausanne). 2020;7:200 [cited 2020 Aug 18]. Available from: https://www.frontiersin.org/article/10.3389/fmed.2020.00200/full.
- Te Velthuis AJW, van den Worm SHE, Sims AC, et al. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176. Available from: https://dx.plos.org/10.1371/journal.ppat.1001176. [cited 2020 Aug 22].
- Ali I, Alharbi OML. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ. 2020;728:138861
- Kojima T, Dogru M, Kawashima M, et al. Advances in the diagnosis and treatment of dry eye. Prog Retin Eye Res. 2020; 100842. doi:10.1016/j.preteyeres.2020.100842. [Cited 2020 Sep 21].
- Calder PC, Carr AC, Gombart AF, et al. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients. 2020;12(4):1181. doi:10.3390/nu12041181. Available from: https://pubmed.ncbi.nlm.nih.gov/32340216/. [cited 2020 Sep 23].
- Ali N, Role of vitamin D in preventing of COVID-19 infection, progresion and severity. J Infect Public Health. 2020;13(10):1373–1380. doi 10.1016/j.jiph.2020.06.021.
- Nguyen TTH, Woo HJ, Kang HK, et al. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnol Lett. 2012;34(5):831–838.
- Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem. 2010;18(22):7940–7947.
- Huang F, Li Y, Leung ELH, et al. A review of therapeutic agents and Chinese herbal medicines against SARS-CoV-2 (COVID-19). Pharmacol Res. 2020;158:104929